|
May 8
|
Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor
|
|
May 2
|
Xyphos and Poseida to develop allogeneic cell therapies for cancer
|
|
May 2
|
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
|
|
Mar 22
|
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
|
|
Mar 20
|
Q4 2023 Taysha Gene Therapies Inc Earnings Call
|
|
Mar 19
|
With new data, Bayer readies rival to Astellas menopause drug
|
|
Jan 8
|
US FDA declines to approve Astellas' gastric cancer drug
|
|
Jan 8
|
Astellas Provides Update on Zolbetuximab Biologics License Application in U.S.
|
|
Dec 28
|
Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager
|
|
Dec 21
|
Astellas Completes Acquisition of Propella Therapeutics
|
|
Dec 10
|
Astellas' VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause
|
|
Nov 30
|
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
|
|
Nov 29
|
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy
|
|
Nov 17
|
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
|
|
Nov 16
|
Paper details Astellas gene therapy study that led to patient deaths
|
|
Nov 16
|
University of Tsukuba and Astellas Confirm a Strategic Partnership
|
|
Nov 15
|
Astellas to Acquire Propella Therapeutics
|
|
Nov 15
|
Astellas Announces Data from ASPIRO Study in X-linked Myotubular Myopathy Published in The Lancet Neurology
|
|
Nov 4
|
IZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 Years
|
|
Aug 9
|
Astellas to Open New Life Sciences Facility in DivcoWest's Cambridge Crossing Neighborhood
|